The bill seeks to improve patient access to biomarker testing, which is essential for diagnosing and managing various medical conditions. It amends several chapters of the General Laws to ensure that biomarker testing is covered under health insurance plans for active and retired employees of the Commonwealth, Medicaid recipients, and individuals with private insurance. The legislation defines key terms such as "biomarker," "biomarker testing," and "nationally recognized clinical practice guidelines," establishing a framework for acceptable testing and coverage criteria. Coverage is mandated when tests are supported by medical evidence, including FDA approvals and clinical guidelines.

Furthermore, the bill amends Chapter 176G of the General Laws to require coverage for biomarker testing in health maintenance contracts, specifying that such testing must be provided for diagnosis, treatment, management, or monitoring of an enrollee's disease when backed by medical evidence. It outlines requirements for prior authorization processes, mandating timely responses from health carriers or utilization review organizations, with expedited responses required in cases of significant health risks. The bill also emphasizes the importance of accessible processes for patients and healthcare providers to request exceptions to coverage policies, ultimately aiming to enhance patient care by ensuring timely access to necessary biomarker testing.